Adjustable intragastric balloons: A 12-month pilot trial in endoscopic weight loss management

Evzen MacHytka, Pavel Klvana, Asher Kornbluth, Steven Peikin, Lisbeth E M Mathus-Vliegen, Christopher Gostout, Gontrand Lopez-Nava, Scott Shikora, Jeffrey Brooks

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Intragastric balloons are associated with (1) early period intolerance, (2) diminished effect within 3-4 months, and (3) bowel obstruction risk mandating removal at 6 months. The introduction of an adjustable balloon could improve comfort and offer greater efficacy. A migration prevention function, safely enabling prolonged implantation, could improve efficacy and weight maintenance post-extraction. The first implantations of an adjustable balloon with an attached migration prevention anchor are reported. The primary endpoint was the absence of bowel perforation, obstruction, or hemorrhage. Eighteen patients with mean BMI of 37.3 were implanted with the Spatz Adjustable Balloon system (ABS) for 12 months. Balloon volumes were adjusted for intolerance or weight loss plateau. Mean weight loss at 24 weeks was 15.6 kg with 26.4% EWL (percent of excess weight loss) and 24.4 kg with 48.8% EWL at 52 weeks. Sixteen adjustments were successfully performed. Six downward adjustments alleviated intolerance, yielding additional mean weight loss of 4.6 kg. Ten upward adjustments for weight loss plateau yielded a mean additional weight loss of 7 kg. Seven balloons were removed prematurely. Complications necessitating early removal included valve malfunction (1), gastritis (1), Mallory-Weiss tear (1), NSAID (2× dose/2 weeks) perforating ulcer (1), and balloon deflation (1). Two incidents of catheter shear from the chain: one passed uneventfully and one caused an esophageal laceration without perforation during extraction. The Spatz ABS has been successfully implanted in 18 patients. (1) Upward adjustments yielded additional weight loss. (2) Downward adjustments alleviated intolerance, with continued weight loss. (3) Preliminary 1-year implantation results are encouraging.

Original languageEnglish (US)
Pages (from-to)1499-1507
Number of pages9
JournalObesity Surgery
Volume21
Issue number10
DOIs
StatePublished - Oct 2011

Fingerprint

compound A 12
Weight Loss
Mallory-Weiss Syndrome
Lacerations
Non-Steroidal Anti-Inflammatory Agents
Gastritis
Ulcer
Catheters
Maintenance
Hemorrhage
Weights and Measures

Keywords

  • "Holiday" period
  • Adjustable balloon
  • Inflation tube
  • Intragastric balloon
  • Prolonged implantation
  • Weight loss

ASJC Scopus subject areas

  • Surgery
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

MacHytka, E., Klvana, P., Kornbluth, A., Peikin, S., Mathus-Vliegen, L. E. M., Gostout, C., ... Brooks, J. (2011). Adjustable intragastric balloons: A 12-month pilot trial in endoscopic weight loss management. Obesity Surgery, 21(10), 1499-1507. https://doi.org/10.1007/s11695-011-0424-z

Adjustable intragastric balloons : A 12-month pilot trial in endoscopic weight loss management. / MacHytka, Evzen; Klvana, Pavel; Kornbluth, Asher; Peikin, Steven; Mathus-Vliegen, Lisbeth E M; Gostout, Christopher; Lopez-Nava, Gontrand; Shikora, Scott; Brooks, Jeffrey.

In: Obesity Surgery, Vol. 21, No. 10, 10.2011, p. 1499-1507.

Research output: Contribution to journalArticle

MacHytka, E, Klvana, P, Kornbluth, A, Peikin, S, Mathus-Vliegen, LEM, Gostout, C, Lopez-Nava, G, Shikora, S & Brooks, J 2011, 'Adjustable intragastric balloons: A 12-month pilot trial in endoscopic weight loss management', Obesity Surgery, vol. 21, no. 10, pp. 1499-1507. https://doi.org/10.1007/s11695-011-0424-z
MacHytka E, Klvana P, Kornbluth A, Peikin S, Mathus-Vliegen LEM, Gostout C et al. Adjustable intragastric balloons: A 12-month pilot trial in endoscopic weight loss management. Obesity Surgery. 2011 Oct;21(10):1499-1507. https://doi.org/10.1007/s11695-011-0424-z
MacHytka, Evzen ; Klvana, Pavel ; Kornbluth, Asher ; Peikin, Steven ; Mathus-Vliegen, Lisbeth E M ; Gostout, Christopher ; Lopez-Nava, Gontrand ; Shikora, Scott ; Brooks, Jeffrey. / Adjustable intragastric balloons : A 12-month pilot trial in endoscopic weight loss management. In: Obesity Surgery. 2011 ; Vol. 21, No. 10. pp. 1499-1507.
@article{9619d357c3bf4f3d849f590b9d3be17a,
title = "Adjustable intragastric balloons: A 12-month pilot trial in endoscopic weight loss management",
abstract = "Intragastric balloons are associated with (1) early period intolerance, (2) diminished effect within 3-4 months, and (3) bowel obstruction risk mandating removal at 6 months. The introduction of an adjustable balloon could improve comfort and offer greater efficacy. A migration prevention function, safely enabling prolonged implantation, could improve efficacy and weight maintenance post-extraction. The first implantations of an adjustable balloon with an attached migration prevention anchor are reported. The primary endpoint was the absence of bowel perforation, obstruction, or hemorrhage. Eighteen patients with mean BMI of 37.3 were implanted with the Spatz Adjustable Balloon system (ABS) for 12 months. Balloon volumes were adjusted for intolerance or weight loss plateau. Mean weight loss at 24 weeks was 15.6 kg with 26.4{\%} EWL (percent of excess weight loss) and 24.4 kg with 48.8{\%} EWL at 52 weeks. Sixteen adjustments were successfully performed. Six downward adjustments alleviated intolerance, yielding additional mean weight loss of 4.6 kg. Ten upward adjustments for weight loss plateau yielded a mean additional weight loss of 7 kg. Seven balloons were removed prematurely. Complications necessitating early removal included valve malfunction (1), gastritis (1), Mallory-Weiss tear (1), NSAID (2× dose/2 weeks) perforating ulcer (1), and balloon deflation (1). Two incidents of catheter shear from the chain: one passed uneventfully and one caused an esophageal laceration without perforation during extraction. The Spatz ABS has been successfully implanted in 18 patients. (1) Upward adjustments yielded additional weight loss. (2) Downward adjustments alleviated intolerance, with continued weight loss. (3) Preliminary 1-year implantation results are encouraging.",
keywords = "{"}Holiday{"} period, Adjustable balloon, Inflation tube, Intragastric balloon, Prolonged implantation, Weight loss",
author = "Evzen MacHytka and Pavel Klvana and Asher Kornbluth and Steven Peikin and Mathus-Vliegen, {Lisbeth E M} and Christopher Gostout and Gontrand Lopez-Nava and Scott Shikora and Jeffrey Brooks",
year = "2011",
month = "10",
doi = "10.1007/s11695-011-0424-z",
language = "English (US)",
volume = "21",
pages = "1499--1507",
journal = "Obesity Surgery",
issn = "0960-8923",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Adjustable intragastric balloons

T2 - A 12-month pilot trial in endoscopic weight loss management

AU - MacHytka, Evzen

AU - Klvana, Pavel

AU - Kornbluth, Asher

AU - Peikin, Steven

AU - Mathus-Vliegen, Lisbeth E M

AU - Gostout, Christopher

AU - Lopez-Nava, Gontrand

AU - Shikora, Scott

AU - Brooks, Jeffrey

PY - 2011/10

Y1 - 2011/10

N2 - Intragastric balloons are associated with (1) early period intolerance, (2) diminished effect within 3-4 months, and (3) bowel obstruction risk mandating removal at 6 months. The introduction of an adjustable balloon could improve comfort and offer greater efficacy. A migration prevention function, safely enabling prolonged implantation, could improve efficacy and weight maintenance post-extraction. The first implantations of an adjustable balloon with an attached migration prevention anchor are reported. The primary endpoint was the absence of bowel perforation, obstruction, or hemorrhage. Eighteen patients with mean BMI of 37.3 were implanted with the Spatz Adjustable Balloon system (ABS) for 12 months. Balloon volumes were adjusted for intolerance or weight loss plateau. Mean weight loss at 24 weeks was 15.6 kg with 26.4% EWL (percent of excess weight loss) and 24.4 kg with 48.8% EWL at 52 weeks. Sixteen adjustments were successfully performed. Six downward adjustments alleviated intolerance, yielding additional mean weight loss of 4.6 kg. Ten upward adjustments for weight loss plateau yielded a mean additional weight loss of 7 kg. Seven balloons were removed prematurely. Complications necessitating early removal included valve malfunction (1), gastritis (1), Mallory-Weiss tear (1), NSAID (2× dose/2 weeks) perforating ulcer (1), and balloon deflation (1). Two incidents of catheter shear from the chain: one passed uneventfully and one caused an esophageal laceration without perforation during extraction. The Spatz ABS has been successfully implanted in 18 patients. (1) Upward adjustments yielded additional weight loss. (2) Downward adjustments alleviated intolerance, with continued weight loss. (3) Preliminary 1-year implantation results are encouraging.

AB - Intragastric balloons are associated with (1) early period intolerance, (2) diminished effect within 3-4 months, and (3) bowel obstruction risk mandating removal at 6 months. The introduction of an adjustable balloon could improve comfort and offer greater efficacy. A migration prevention function, safely enabling prolonged implantation, could improve efficacy and weight maintenance post-extraction. The first implantations of an adjustable balloon with an attached migration prevention anchor are reported. The primary endpoint was the absence of bowel perforation, obstruction, or hemorrhage. Eighteen patients with mean BMI of 37.3 were implanted with the Spatz Adjustable Balloon system (ABS) for 12 months. Balloon volumes were adjusted for intolerance or weight loss plateau. Mean weight loss at 24 weeks was 15.6 kg with 26.4% EWL (percent of excess weight loss) and 24.4 kg with 48.8% EWL at 52 weeks. Sixteen adjustments were successfully performed. Six downward adjustments alleviated intolerance, yielding additional mean weight loss of 4.6 kg. Ten upward adjustments for weight loss plateau yielded a mean additional weight loss of 7 kg. Seven balloons were removed prematurely. Complications necessitating early removal included valve malfunction (1), gastritis (1), Mallory-Weiss tear (1), NSAID (2× dose/2 weeks) perforating ulcer (1), and balloon deflation (1). Two incidents of catheter shear from the chain: one passed uneventfully and one caused an esophageal laceration without perforation during extraction. The Spatz ABS has been successfully implanted in 18 patients. (1) Upward adjustments yielded additional weight loss. (2) Downward adjustments alleviated intolerance, with continued weight loss. (3) Preliminary 1-year implantation results are encouraging.

KW - "Holiday" period

KW - Adjustable balloon

KW - Inflation tube

KW - Intragastric balloon

KW - Prolonged implantation

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=80755190129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755190129&partnerID=8YFLogxK

U2 - 10.1007/s11695-011-0424-z

DO - 10.1007/s11695-011-0424-z

M3 - Article

C2 - 21553304

AN - SCOPUS:80755190129

VL - 21

SP - 1499

EP - 1507

JO - Obesity Surgery

JF - Obesity Surgery

SN - 0960-8923

IS - 10

ER -